

Dr.C.K. Atal conferred the EDPA award of appreciation for outstanding contributions in drug development and Piperine research

Dr C K Atal has been given the East Delhi Physician's association award of appreciation for outstanding contributions in drug development at a ceremony at Hotel Lemon tree, East Delhi mall, Kaushambi. The event was held on occasion of medical conference Midcon 2014, with theme "Infections update" organized by EDPA on 27th July 2014 and attended by a large gathering of more than 130 leading Physicians and super specialists of east Delhi and other adjoining areas.

The award was given for pioneering contributions of Dr. C. K. Atal, for the scientific validation and discovery of world's first bioenhancer Piperine, for scientifically establishing a new chapter of Bioenhancers in Medical science and for initiating the bioenhanced antitubercular research project which resulted in the development of world's first bioenhanced antitubercular formulation Risorine developed by IIM (CSIR).

This bioenhanced anti tubercular formulation Risorine is based on a patented pioneering discovery of world's first bioenhancer Piperine discovered and reported by Dr. Atal in IDMA bulletin in 1979. Dr. C. K. Atal has been the former Director and Piperine research team leader at IIM Jammu, formerly called RRL Jammu.

Dr.Atal has earlier also been awarded the Indian Medical association "Chikitsa seva rattan" award for the same discovery at IMA bhawan Delhi (IMA-EDB) in 2010.

This approved drug was released by IIM Jammu, CSIR and Cadila Pharmaceuticals in the market in 2009 as public private partnership and officially released by CSIR, IIM-Jammu, and Government of India (Ministry of Science and technology) on world Tuberculosis day 2011 at Anusandhan Bhawan, Rafi Marg, Delhi. Same day it was also presented by minister of science and technology to world dignitary Mr. Bill Gates, chairman of Microsoft at Hotel Le Meridian, Delhi.

The bioenhancer drug Piperine makes several classes of existing modern drugs safer, cheaper and more efficacious even at a lower dose. It is a boon to the economically poor ill patients and a great savings to the country. It is primarily targeted for Toxic drugs, poorly bioavailable drugs, scarce drugs, or for drugs which are given for long periods like anti TB drugs. This research has established a new chapter in medical science and made India a global pioneer in bioenhancers.